These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Thom Award Lecture. Trends in the search for bioactive microbial metabolites. Omura S J Ind Microbiol; 1992 Sep; 10(3-4):135-56. PubMed ID: 1368867 [TBL] [Abstract][Full Text] [Related]
45. A tribute to Leo C Vining. Magarvey NA; Demain AL J Antibiot (Tokyo); 2013 Jul; 66(7):359-60. PubMed ID: 23892548 [No Abstract] [Full Text] [Related]
46. Solvent Tolerance in Bacteria: Fulfilling the Promise of the Biotech Era? Kusumawardhani H; Hosseini R; de Winde JH Trends Biotechnol; 2018 Oct; 36(10):1025-1039. PubMed ID: 29778531 [TBL] [Abstract][Full Text] [Related]
47. Oligotrophic micro-organisms in industry, medicine and the environment. Wainwright M; Barakah F; al-Turk I; Ali TA Sci Prog; 1991; 75(298 Pt 3-4):313-22. PubMed ID: 1842853 [TBL] [Abstract][Full Text] [Related]
48. Bacterial symbionts: prospects for the sustainable production of invertebrate-derived pharmaceuticals. Piel J Curr Med Chem; 2006; 13(1):39-50. PubMed ID: 16457638 [TBL] [Abstract][Full Text] [Related]
49. [Study of the conditions for reproducing the processes of antibiotic biosynthesis. Determining the limiting stage of the process of mass transfer of oxygen]. Kuz'mina LM; Biriukov VV Antibiot Khimioter; 1990 Mar; 35(3):3-6. PubMed ID: 2193632 [TBL] [Abstract][Full Text] [Related]
50. Antibiotics. BÄ•hal V Biotechnol Annu Rev; 2002; 8():227-65. PubMed ID: 12436921 [TBL] [Abstract][Full Text] [Related]
51. Environmentally directed mutations and their impact on industrial biotransformation and fermentation processes. Zelder O; Hauer B Curr Opin Microbiol; 2000 Jun; 3(3):248-51. PubMed ID: 10851161 [TBL] [Abstract][Full Text] [Related]
53. Biotechnological potentials of anoxygenic phototrophic bacteria. I. Production of single-cell protein, vitamins, ubiquinones, hormones, and enzymes and use in waste treatment. Sasikala C; Ramana CV Adv Appl Microbiol; 1995; 41():173-226. PubMed ID: 7572333 [No Abstract] [Full Text] [Related]
54. Biological stereoselectivity of atropisomeric natural products and drugs. Zask A; Murphy J; Ellestad GA Chirality; 2013 May; 25(5):265-74. PubMed ID: 23620262 [TBL] [Abstract][Full Text] [Related]
55. Screening microbial metabolites for new drugs--theoretical and practical issues. Yarbrough GG; Taylor DP; Rowlands RT; Crawford MS; Lasure LL J Antibiot (Tokyo); 1993 Apr; 46(4):535-44. PubMed ID: 8500997 [No Abstract] [Full Text] [Related]
57. Microbial secondary metabolism: a new theoretical frontier for academia, a new opportunity for industry. Demain AL Ciba Found Symp; 1992; 171():3-16; discussion 16-23. PubMed ID: 1302184 [TBL] [Abstract][Full Text] [Related]
58. Chemical signaling among bacteria and its inhibition. Lyon GJ; Muir TW Chem Biol; 2003 Nov; 10(11):1007-21. PubMed ID: 14652068 [TBL] [Abstract][Full Text] [Related]
59. [Pilot plant for microbiological synthesis. Engineer and technological aspects]. Lukanin AV Antibiot Khimioter; 2007; 52(9-10):50-5. PubMed ID: 20583471 [TBL] [Abstract][Full Text] [Related]
60. Biology and applications of co-produced, synergistic antimicrobials from environmental bacteria. Meyer KJ; Nodwell JR Nat Microbiol; 2021 Sep; 6(9):1118-1128. PubMed ID: 34446927 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]